Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies (Q41593651)
Jump to navigation
Jump to search
scientific article published on 9 March 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies |
scientific article published on 9 March 2015 |
Statements
1 reference
Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies (English)
1 reference
Maria Gavriatopoulou
1 reference
Evangelos Terpos
1 reference
Magdalini Migkou
1 reference
Maria Roussou
1 reference
Erasmia Psimenou
1 reference
Savvas T Toumanidis
1 reference
Argyrios Ntalianis
1 reference
Anna Tasidou
1 reference
Despina Kalapanida
1 reference
Constantinos Pamboucas
1 reference
Elisavet Kaldara
1 reference
9 March 2015
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference